The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment patterns of gastrointestinal neuroendocrine tumors (NET).
 
Michael S. Broder
Other Relationship - Novartis
 
Eunice Chang
Other Relationship - Novartis
 
Beilei Cai
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Honoraria - Novartis
Travel, Accommodations, Expenses - Novartis
 
Maureen Neary
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Elya Papoyan
Other Relationship - Novartis
 
Al Bowen Benson
Consulting or Advisory Role - Alchemia; Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech/Roche; Genomic Health; Infinity Pharmaceuticals; IntegraGen; Lilly/ImClone; Merck Serono; Merck/Schering Plough; National Cancer Institute; Pharmacyclics; Precision Therapeutics; Sanofi; Spectrum Pharmaceuticals; Taiho Pharmaceutical; Vicus Therapeutics
Research Funding - advanced accelerator applications; Alchemia; Amgen; Astellas Pharma; AVEO; Bayer/Onyx; EMD Serono (Inst); Genentech (I); Gilead Sciences; Infinity Pharmaceuticals; Merck Serono (Inst); Novartis
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Bayer; Boehringer Ingelheim; Dava Oncology; Genentech/Roche; Gilead Sciences; Lilly/ImClone; Sanofi; Spectrum Pharmaceuticals; TRM Oncology